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ABSTRACT
Merkel cell carcinoma (MCC) is an aggressive skin cancer of neuroendocrine origin with a high propensity for recurrence and
metastasis. Merkel cell polyomavirus (MCPyV) causes the majority of MCC cases due to the expression of the MCPyV small and
large tumor antigens (ST and LT, respectively). Although a number of molecular mechanisms have been attributed to MCPyV
tumor antigen-mediated cellular transformation or replication, to date, no studies have investigated any potential link between
MCPyV T antigen expression and the highly metastatic nature of MCC. Here we use a quantitative proteomic approach to show
that MCPyV ST promotes differential expression of cellular proteins implicated in microtubule-associated cytoskeletal organiza-
tion and dynamics. Intriguingly, we demonstrate that MCPyV ST expression promotes microtubule destabilization, leading to a
motile and migratory phenotype. We further highlight the essential role of the microtubule-associated protein stathmin in
MCPyV ST-mediated microtubule destabilization and cell motility and implicate the cellular phosphatase catalytic subunit pro-
tein phosphatase 4C (PP4C) in the regulation of this process. These findings suggest a possible molecular mechanism for the
highly metastatic phenotype associated with MCC.
IMPORTANCE
Merkel cell polyomavirus (MCPyV) causes the majority of cases of Merkel cell carcinoma (MCC), an aggressive skin cancer with
a high metastatic potential. However, the molecular mechanisms leading to virally induced cancer development have yet to be
fully elucidated. In particular, no studies have investigated any potential link between the virus and the highly metastatic nature
of MCC. We demonstrate that the MCPyV small tumor antigen (ST) promotes the destabilization of the host cell microtubule
network, which leads to a more motile and migratory cell phenotype. We further show that MCPyV ST induces this process by
regulating the phosphorylation status of the cellular microtubule-associated protein stathmin by its known association with the
cellular phosphatase catalytic subunit PP4C. These findings highlight stathmin as a possible biomarker of MCC and as a target
for novel antitumoral therapies.
Merkel cell carcinoma (MCC) is an aggressive skin tumor (1).The reported cases of MCC have tripled in the past 20 years
in both Europe and the United States (2), due to an increase in
known risk factors—UV exposure, immune suppression, and in-
creased age (1, 3). The cancer is characterized by significant inci-
dence of local recurrence, early involvement of local lymph nodes,
and distant metastasis (4). As such, MCC has a poor 5-year sur-
vival rate, due to its high propensity to metastasize (5).
Merkel cell polyomavirus (MCPyV) is clonally integrated in
80% of MCC tumors (6). MCPyV encodes both large and small
T antigens (LT and ST, respectively), which are regulatory pro-
teins required for viral replication and tumorigenesis (6). MCPyV
infection and integration occur prior to expansion and metastasis
of the tumor (7, 8), and truncation mutations of the LT gene are
observed in the integrated genome rendering the virus replication
defective (6). LT and ST are required for MCC cell survival and
proliferation, as depletion of these T antigens leads to cell arrest
and death of MCPyV-positive MCC cells (9). In contrast to simian
virus 40 (SV40), MCPyV ST is sufficient to transform rodent cells
to anchorage- and contact-independent growth and also induces
serum-free proliferation of human cells (10). However, the exact
contribution of ST to MCC cell growth is under debate as several
ST depletion studies have shown differential dependence for MCC
proliferation (11, 12). Recent analyses suggest that MCPyV ST is
multifunctional in nature (13). MCPyV ST leads to the hyper-
phosphorylation of 4E-BP1, resulting in the deregulation of cap-
dependent translation, (10), it targets the cellular ubiquitin ligase
SCFFwb7, stabilizing MCPyV LT and several cellular oncoproteins
(14), and also functions as an inhibitor of NF-B-mediated tran-
scription (15). Although these interactions are attributed to either
MCPyV ST-mediated cellular transformation or MCPyV replica-
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tion processes, to date, no studies have investigated any potential
link between MCPyV T antigen expression and the highly meta-
static nature of MCC. This is of significant importance as dissem-
ination and metastasis correlate with poor MCC survival rates
(16).
Despite the clinical importance, the molecular basis by which
cancer cells acquire the capability to migrate from the primary
tumor remains to be fully elucidated (17). What is clear is that cell
motility, migration, and invasion are critical factors regulating
dissemination (18, 19). The importance of the actin cytoskeletal
network in cell motility and migration has since been established
(20), and in recent years, it has become evident that the microtu-
bule network also has an important role in facilitating cell motility
and migration (21, 22).
Microtubules are essential components of the cytoskeleton and
play a crucial role in a variety of cellular functions from the posi-
tioning of organelles, providing tracts for long distance transport,
to ensuring the correct and timely segregation of chromosomes
during mitosis (23–26). Furthermore, the microtubule network is
central in controlling cell shape and polarized cell motility (21,
22). Microtubules are composed of -tubulin heterodimers,
which self-assemble and disassemble, allowing transitions be-
tween microtubule growth and microtubule shrinkage or catas-
trophe (27, 28). This dynamic process is regulated by microtu-
bule-stabilizing and -destabilizing proteins (23, 29). One such
microtubule-associated protein (MAP) is stathmin, also known as
oncoprotein-18 (30–32). In its unphosphorylated form, stathmin
binds and sequesters tubulin dimers, forming a T2S complex and
thereby reducing the substrate for growing microtubule polymers,
thus indirectly leading to microtubule destabilization. In contrast,
phosphorylation of stathmin at one or more serine residues weak-
ens the tubulin-binding ability of stathmin and increases free tu-
bulin concentrations for microtubule assembly (33, 34).
Stathmin overexpression is a feature of multiple cancer types
and correlates with poor prognosis and high metastatic potential
(35, 36). As such, alterations in the microtubule network by stath-
min deregulation play a crucial role in cell motility, migration, and
invasion. This is supported by RNA interference (RNAi) studies
showing that a reduction in stathmin correlates with reduced cell
migration in various cancers (37–40). Moreover, regulation of the
phosphorylation status of stathmin can affect its microtubule-
destabilizing activity and transforming potential (41, 42). To-
gether these observations highlight an important link between
stathmin, microtubule dynamics, and cell motility in cancer.
Herein we utilized quantitative proteomics to examine the ef-
fect of MCPyV ST on the host cell proteome. Intriguingly MCPyV
ST promotes differential expression of cellular proteins impli-
cated in microtubule-associated cytoskeletal organization and dy-
namics, leading to a motile and migratory phenotype. Specifically,
we demonstrate that stathmin is required for MCPyV ST-medi-
ated microtubule destabilization and cell motility. Moreover, reg-
ulation of this process involves the cellular phosphatase catalytic
subunit protein phosphatase 4C (PP4C).
MATERIALS AND METHODS
Plasmids, siRNAs, and antibodies. Expression vectors for enhanced
green fluorescent protein (EGFP)-ST, EGFP-R7A, and EGFP-ST95-111
have been previously described (15). Wild-type EE-PP2A (protein phos-
phatase 2A), FLAG-PP4C, and transdominant mutants PP2AcH118N
and RL-PP4C-HA (hemagglutinin) were kindly provided by Stefan Stack,
Marilyn Goudrealt, Brian Hemmings and Tse-Hua Tan, respectively.
Stathmin-specific small interfering RNAs (siRNAs) were purchased
from Qiagen. Lentivirus-based vectors expressing short hairpin RNAs
(shRNAs) targeting T antigens were kindly provided by Masahiro Shuda
and Pat Moore (10, 11). Antibodies against stathmin, STRAP, -tubulin,
lamin B, Glu-Glu, Kif14, GAPDH (glyceryaldehyde-3-phosphate dehy-
drogenase) (Abcam), phosphorylated stathmin, acetylated tubulin (Cell
Signaling), dynamin, TBCC (Genetex), FLAG, -actin (Sigma-Aldrich),
and GFP (Living Colors) were purchased from their respective suppliers.
The 2T2 antibody was kindly provided by Christopher Buck. Western blot
analysis was carried out using specific antibodies at dilutions of 1:1,000
and 1:250, as previously described (43, 44).
Cells. i293-ST cells, previously described (15), were maintained in
Dulbecco’s modified Eagle’s medium (DMEM) containing 10% fetal bo-
vine serum (FBS) and 1% penicillin–streptomycin (45, 46). MCC13 and
MKL-1 cell lines were maintained in RPMI 1640 medium supplemented
with 10% FBS and 1% penicillin–streptomycin. ST-FLAG expression was
induced from i293-ST with 2 g/ml doxycycline hyclate for up to 48 h
(15).
SILAC-based quantitative proteomics. The protocol for stable iso-
tope labeling by amino acids in cell culture (SILAC) was performed as
previously described (47, 48). Essentially i293-ST cells in each 5- by 175-
cm2 flask containing R6K4 (uninduced) or R0K0 (induced with doxycy-
cline hyclate) were washed and incubated in buffer A for 15 min. The
cytoplasm was ruptured using a prechilled Dounce homogenizer. Nuclear
pellets were washed in sucrose solution. The R0K0- and R6K4-treated
samples were combined for each cellular compartment in a 1:1 ratio, and
proteins were separated by SDS-PAGE. Ten gel slices per fraction were
extracted and subjected to in-gel digestion using trypsin. Purified peptides
were identified using an LTQ-Orbitrap Velos mass spectrometer (Univer-
sity of Bristol Proteomics Facility). Peptide identification and quantifica-
tion were performed using MaxQuant (49), based on the two-dimen-
sional (2D) centroid of the isotope clusters within each SILAC pair. The
derived peak list was searched with the Mascot search engine (version
2.1.04; Matrix Science, London, United Kingdom) against a concatenated
database combining 80,412 proteins from the International Protein Index
human protein database version 3.6. For quantitative analysis, a 2.0-fold
cutoff was chosen as a basis for investigating potential proteome changes
(50), using the Database for Annotation, Visualization and Integrated
Discovery (DAVID) v6.7 (51).
Immunoblotting. Cells were lysed in radioimmunoprecipitation as-
say (RIPA) buffer supplemented with protease inhibitor cocktail (Roche)
(52). Proteins were separated by SDS-PAGE before transfer onto nitrocel-
lulose membrane (Hybond C Extra; Amersham Biosciences). Membranes
were probed with the appropriate primary and horseradish peroxidase
(HRP)-conjugated secondary antibodies. Proteins were detected using
EZ-ECL enhancer solution (Geneflow) as previously described (53).
Live cell imaging. Cell motility was analyzed using an Incucyte kinetic
live cell imaging system as directed by the manufacturer. A 96-well plate
was seeded with cells at a density of 3,000 cells per well. After 12 h, the cells
were transfected with 250 ng of DNA/well. Twelve hours later, the trans-
fection medium was changed for 10% Hams F-12 medium, and imaging
was started. Imaging was performed for a 24-h period, with images taken
every 30 min. Cell motility was then tracked using Image J software (54).
Multicolour immunohistochemistry. Formalin-fixed, paraffin-em-
bedded (FFPE) sections from primary MCC tumors were prepared and
analyzed as previously described (55). The primary antibodies were cyto-
keratin 20 (CK20) antibody (dilution 1:50 [Dako]), MCPyV LT antibody
CM2B4 (dilution 1:125 [Santa Cruz Biotechnology]), and anti-stathmin 1
antibody (dilution 1:250 [Abcam]). An isotype-matched irrelevant anti-
body was used as a negative control on serial sections of tissues in parallel,
Dako X0943 was used for the CK20 primary antibody, and the rabbit
polyclonal isotype control antibody (Abcam) was used to match the stath-
min primary antibody. Sections were incubated with appropriate second-
ary antibodies labeled with different fluorochromes: Alexa Fluor 488
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IgG2B and Alexa Fluor 633 IgG2A [Invitrogen] and IgG (HL)-tetram-
ethyl rhodamine isocyanate (TRITC) (Jackson ImmunoResearch). Nu-
clear counterstaining was with bis-benzimide (Invitrogen). All slides were
mounted with Immu-Mount, and images were captured with a Zeiss LSM
510 confocal microscope (56).
Scratch wound-healing assay. Poly-L-lysine-coated 6-well plates were
seeded with cells, and the cells were allowed to adhere for 24 h. The cells
were then subjected to a scratch using a p1000 pipette tip in a continuous
straight line through the well. Images were taken under a Zeiss light mi-
croscope at a 	4 magnification at 0, 24, 48, and 72 h postscratch (57).
Paclitaxel-based scratch assays were incubated for 4 h with 10 M pacli-
taxel after induction for 24 h. siRNA and expression plasmids were trans-
fected 24 h prior to the scratch.
Invasion and migration assays. BD BioCoat angiogenesis system as-
say kits (an endothelial cell migration kit coated with human fibronectin
and endothelial cell invasion kit coated with Matrigel) were used as de-
scribed by the manufacturer’s protocol. All conditions were the same for
assays performed in triplicate.
Immunofluorescence. Immunofluorescence was carried out as previ-
ously described. Cells were viewed on a Zeiss 510 confocal microscope
under an oil immersion 63	 objective lens. Images were analyzed using
the LSM imaging software and are presented as z-stacked images (58).
RESULTS
MCPyV ST affects microtubule network regulatory proteins. To
analyze the effect of MCPyV ST expression on the cellular pro-
teome, SILAC-based quantitative proteomics was performed uti-
lizing a 293 Flp-In cell line capable of inducible MCPyV ST ex-
pression, termed i293-ST (15). The i293-ST line is a robust model
for this analysis, as inducible levels of MCPyV ST are representa-
tive of ST expression in an MCPyV-positive MCC cell line, MKL-1
(Fig. 1A). Bioinformatic analysis using the Database for Annota-
tion, Visualization and Integrated Discovery (DAVID) v6.7 (51)
highlighted that a significant proportion of the highly differen-
tially expressed proteins were implicated in gene ontology group-
ings involving microtubule-associated cytoskeletal organization
and dynamics (see Fig. S1 in the supplemental material), which is
the focus of this study. Figure S2 in the supplemental material
summarizes the differential expression of proteins associated with
other gene ontology groupings.
Of particular interest was the dramatic upregulation (8.33-fold)
of the microtubule-associated protein stathmin, a critical factor for
microtubule dynamics (30). Stathmin is overexpressed in many hu-
man cancers and is implicated in clinical characteristics such as tumor
grade, size, and prognosis (37). To confirm that stathmin and a selec-
tion of other proteins associated with microtubule dynamics were
altered upon MCPyV ST expression, immunoblotting was per-
formed comparing uninduced and induced i293-ST cell lysates (Fig.
1B). The results show an increase in the levels of expression of the
microtubule-associated proteins upon MCPyV ST expression and
support the quantitative proteomic analysis.
To further investigate the differential expression of stathmin
with regard to MCC, multicolor immunohistochemistry analysis
was performed on formalin-fixed, paraffin-embedded (FFPE)
sections of primary MCC tumors. Sections were incubated with
cytokeratin 20 (CK20) (a marker widely used to distinguish MCC)
and stathmin-specific antibodies. An isotype-matched control
was also used as a negative control. The results show demonstrably
higher levels of stathmin expression coincident with CK20 stain-
ing in regions of the tumor (Fig. 1C). These data suggest that MCC
tumor cells express increased levels of stathmin. In addition, mul-
ticolor immunohistochemistry analysis was performed on FFPE
sections of two further MCC tumors to determine the potential
correlation between stathmin expression levels and MCPyV pos-
itivity (Fig. 1D). Sections were stained as described above but were
also incubated with an MCPyV LT-specific antibody. The results
again show abundant levels of stathmin expression coincident
with CK20 staining in both MCC tumors; however, interestingly,
LT expression was much weaker in one of the tumors, suggesting
that other mechanisms of stathmin upregulation may occur in
MCC, including possible virus-independent mechanisms.
MCPyV ST promotes cell motility, migration, and invasion.
To assess whether MCPyV ST promotes a more motile and migra-
tory cell phenotype due to the differential expression of microtu-
bule-associated proteins, live cell imaging was performed using an
Incucyte kinetic live cell imaging system comparing EGFP- with
EGFP-ST-expressing 293 cells. We have previously shown that the
EGFP fusion does not affect ST functioning (15). Cells were im-
aged every 30 min over a 24-h period, and cell motility was tracked
using Image J software (Fig. 2A; see Movies S1 and S2 in the sup-
plemental material). The results show line traces following the cell
motility of 3 distinct cells, demonstrating that MCPyV ST leads to
a statistically significant increase in cell motility. Moreover, imag-
ing demonstrates that in contrast to EGFP-expressing cells, where
cells grow in a colony, MCPyV ST-expressing cells rapidly disso-
ciate from the colonies (as highlighted in the top right section of
the movies in the supplemental material), suggesting a more mo-
tile and migratory phenotype. To confirm this observation, a
scratch assay was performed comparing uninduced versus in-
duced i293-ST cells. Cellular growth back was recorded every 24 h
for a period of 3 days, and the results indicate that, in contrast to
uninduced cells, MCPyV ST enhanced the motility and migration
of cells, fully closing the wound at 72 h (Fig. 2B). To verify this
enhanced motile and migratory phenotype, Matrigel and fi-
bronectin-based Transwell migration and invasion assays were
performed. HT1080 cells, an invasive human fibrosarcoma cell
line, were used as a positive control. The results demonstrate
that both induced i293-ST and EGFP-ST-expressing cells
showed a significant increase in migration and invasive prop-
erties compared to uninduced or EGFP-expressing cells, re-
spectively (Fig. 2C).
Furthermore, to confirm these observations in an MCC cell
line, live cell imaging and Matrigel-based migration assays were
repeated using the MCPyV-negative cell line MCC13, transfected
with either EGFP or EGFP-ST expression constructs. Similar find-
ings were observed in MCC13 cells, where MCPyV ST increased
their cell motility (Fig. 3A) and migration (Fig. 3B). To confirm
that these observations were due to enhanced cell motility, migra-
tion, and invasion and not to increased cell proliferation, assays
were performed in 10% serum levels, the same serum levels used
for all motility assays. The results show no statistical difference in
cell proliferation upon MCPyV ST expression (Fig. 3C). Together
these data suggest that MCPyV ST leads to enhanced cell motility
and migration.
MCPyV ST promotes microtubule destabilization. To inves-
tigate what effect MCPyV ST expression had upon stathmin sub-
cellular localization, immunofluorescence studies were per-
formed in MCC13 cells expressing EGFP or EGFP-ST, using a
stathmin-specific antibody. The results show that endogenous
stathmin has a diffuse cytoplasmic staining in EGFP-expressing
cells. In contrast, upon MCPyV ST expression, stathmin is redis-
tributed to a halo-like pattern around the nucleus, which colocal-
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izes with a portion of MCPyV ST (Fig. 4A). This cytoplasmic halo-
like staining is indicative of a destabilized microtubule network
(31, 59). To determine if the stability of the microtubule network
is altered upon MCPyV ST expression, immunofluorescence
studies were repeated using a -tubulin-specific antibody. In
EGFP-transfected cells, -tubulin highlighted the presence of a
stable microtubule network, whereas in MCPyV ST-expressing
cells, -tubulin relocalized to a halo-like distribution, consistent
with that of stathmin, indicating microtubule network destabili-
zation (Fig. 4B).
FIG 1 MCPyV ST expression leads to the differential expression of proteins involved in microtubule-associated cytoskeletal organization and dynamics. (A) (i)
i293-ST cells were grown in DMEM with R0K0 and induced (IN) for 24 h or grown in DMEM with R6K4 and remained uninduced (UN). Cell lysates were
analyzed by immunoblotting with a FLAG-specific antibody. (ii) To confirm that induced levels of MCPyV ST in i293-ST cells are representative of ST expression
in the MCPyV-positive MCC cell lines, immunoblotting was performed using an MCPyV T-specific antibody comparing cell lysates from 1 	 105 cells of
uninduced and induced i293-ST, MCC13, and MKL-1 cells. (B) i293-ST cells remained uninduced or were incubated for either 24 or 48 h in the presence of
doxycycline hyclate. After induction, cell lysates were analyzed by immunoblotting using a FLAG-specific antibody and a range of microtubule-associated-
specific antibodies highlighted by quantitative proteomic analysis. GAPDH was used as a measure of equal loading. (C) FFPE sections of a primary MCC tumor
were stained with stathmin- and CK20-specific antibodies or an isotype negative control. After washing, sections were incubated with Alexa Fluor-labeled
secondary antibodies. Nuclear staining was performed with bis-benzimide. Slides were then analyzed using a Zeiss LSM 510 confocal laser scanning microscope.
(D) FFPE sections of two additional primary MCC tumors were stained with stathmin-, MCPyV LT-, and CK20-specific antibodies or an isotype negative control.
After washing, sections were incubated with Alexa Fluor-labeled secondary antibodies. Nuclear staining was labeled using bis-benzimide. Slides were then
analyzed using a Zeiss LSM 510 confocal laser scanning microscope.
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To verify that the stability of the microtubule network is altered
upon MCPyV ST expression, immunoblotting was performed us-
ing an acetylated tubulin-specific antibody, a marker of stabilized
microtubules (60) in MCC13 cells transfected with either EGFP or
EGFP-ST (Fig. 4C), or MCPyV-positive (MKL-1) versus the
MCPyV-negative (MCC13) cells (Fig. 4D). Although no overall
change in microtubule levels was observed, as indicated by -tu-
bulin levels, a marked decrease in acetylated tubulin levels was
FIG 2 MCPyV ST promotes cell motility, migration, and invasion. (A) (i) HEK293 cells were transiently transfected with either EGFP or EGFP-ST. After 12 h,
cell motility was analyzed using an Incucyte kinetic live cell imaging system. Images were taken every 30 min for a 24-h period. The movement of cells was then
tracked using Image J software: three cell motility traces for each transfection are shown in each image, colored red, blue, and green. (ii) The average distance
moved by pEGFP- or pEGFP-ST-transfected cells was measured in m (n 
 50). (B) (i) Poly-L-lysine-coated 6-well plates were seeded with i293-ST cells, and
the cells remained uninduced (UN) or were induced (IN) by incubation in the presence of doxycycline hyclate. After 24 h, a scratch was created by scraping the
monolayer using a p1000 pipette tip. Cells were then incubated for a 72-h period in the absence or presence of doxycycline hyclate. Migration of cells toward the
scratch was observed over a 72-h period, and images were taken every 24 h under a Zeiss light microscope at 	4 magnification. (ii) The size of the wound was
measured at 0 and 72 h. Scratch assays were performed in triplicate. (C) Precoated Matrigel and fibronectin-based Transwell migration and invasion tissue
culture plates were seeded with uninduced or induced i293-ST cells and EGFP- versus EGFP-ST-transfected cells. HT1080 cells, an invasive human fibrosarcoma
cell line, were also used as a positive control. Cells were incubated in the Transwell plates for 22 h and then labeled with calcein AM fluorescent dye for 90 min,
and fluorescence was measured. The experiment was performed in triplicate, and the graph indicates the fluorescence (percentage) of cells moving through the
migration and invasion plates relative to the uncoated plate, set at 100%.
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observed upon MCPyV ST expression, indicating a decrease in
stabilized microtubules. Moreover, we also assessed whether
MCPyV ST affects the phosphorylation status of stathmin, using
phospho-stathmin (Ser16) and stathmin-specific antibodies. The
results showed increased stathmin expression, as previously de-
scribed (Fig. 4C and D). However, importantly, the levels of phos-
phorylated stathmin decreased upon MCPyV ST expression (Fig.
4C and D), suggesting that MCPyV ST leads to an increase in the
pool of unphosphorylated stathmin, which in turn promotes mi-
crotubule destabilization.
Microtubule destabilization is required for MCPyV ST-me-
diated cell motility. We next assessed if microtubule destabilization
is essential for MCPyV ST-induced cell motility. The taxane-based
drug paclitaxel binds microtubules, promoting polymerization and
stability (61). Therefore, immunofluorescence studies were con-
ducted to determine whether paclitaxel inhibited MCPyV ST-in-
duced microtubule destabilization. Paclitaxel treatment had no effect
on the stable microtubule network in EGFP-expressing MCC13 cells
(Fig. 5A), resembling EGFP-expressing cells alone (Fig. 4B). How-
ever, paclitaxel inhibited EGFP-ST-mediated microtubule destabili-
zation previously observed in Fig. 4B, since in the presence of the
drug, distinctive bundles of microtubules were visible (Fig. 5A). To
determine if prevention of MCPyV ST-induced microtubule desta-
bilization affects cell motility and migration, scratch assays were per-
formed comparing MCC13 cells expressing EGFP or EGFP-ST (Fig.
5B) in the absence and presence of paclitaxel. The results observed in
the absence of paclitaxel were similar to those of Fig. 2B, demonstrat-
ing that MCPyV ST enhances cell motility and migration. In contrast,
in the presence of paclitaxel, EGFP-ST-transfected MCC13 cells mi-
grate at the same speed as EGFP-expressing MCC13 cells (Fig. 5B).
These data suggest that MCPyV ST-mediated microtubule destabili-
zation is required to enhance cell motility and migration, and the use
of a microtubule-stabilizing drug can inhibit this function.
To confirm that MCPyV ST-induced microtubule destabiliza-
tion is required for cell motility, depletion of ST was performed in
the MCPyV-positive MKL-1 cell line using lentivirus-based vec-
tors expressing shRNAs targeting ST alone, both LT and ST
(“PanT” in Fig. 5B), and a scrambled negative control (10, 11).
Results show that effective ST knockdown led to reduced levels of
stathmin induction but increased levels of phosphorylated stath-
min and acetylated tubulin, indicating increased microtubule sta-
bilization compared to the scrambled control (Fig. 5C). This con-
FIG 3 MCPyV ST promotes cell motility and migration in MCC13 cells. (A) (i) MCC13 cells were transiently transfected with either EGFP or EGFP-ST
expression vectors. After 12 h, cell motility was analyzed using an Incucyte kinetic live cell imaging system. Images were taken every 30 min for a 24-h period. The
movement of cells was then tracked using Image J software: four cell motility traces for each transfection are shown in each image, colored red, blue, cyan, and
yellow. (ii) The average distance moved by EGFP- or EGFP-ST-transfected cells was measured in m (n 
 50). (B) Precoated Matrigel-based Transwell migration
tissue culture plates were seeded with EGFP- versus EGFP-ST-transfected MCC13 cells. HT1080 cells, an invasive human fibrosarcoma cell line, were also used
as a positive control. Cells were incubated in the Transwell plates for 22 h and then labeled with calcein AM fluorescent dye for 90 min, and fluorescence was
measured. The experiment was performed in triplicate, and the graph indicates the fluorescence (percentage) of cells moving through the migration plates
relative to the uncoated plate, set at 100%. (C) A 6-well plate was seeded with 1 	 104 uninduced or induced i293-ST cells and EGFP- versus EGFP-ST-transfected
cells in DMEM–10% FCS, and the number of cells was counted every 24 h for a period of 3 days (n 
 3).
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firms that MCPyV ST is required for microtubule destabilization.
Moreover, MKL-1 cells transduced with scrambled control-, ST-,
or ST/LT-targeting lentivirus-based vectors were assessed for their
ability to migrate in a Matrigel-based assay specific for nonadher-
ent cells (62) (Fig. 5D). The results show that MCPyV ST deple-
tion significantly reduced the motility of MKL-1 cells.
Stathmin depletion inhibits MCPyV ST-mediated cell motil-
ity. An important caveat to the paclitaxel experiment is that treat-
ment of MCPyV ST-expressing cells with taxane-based drugs may
also have an effect on cell division, preventing regrowth into the
scratch. To overcome this and address the specific role of stathmin
in MCPyV ST-mediated cell motility, scratch assays were per-
formed comparing uninduced versus induced i293-ST cells,
which were specifically depleted of stathmin (Fig. 6A). This exper-
iment was performed with i293-ST cells due to the inability to
effectively deplete stathmin levels in MKL-1 cells. i293-ST cells
were initially transfected with either control scrambled or stath-
min-specific siRNAs, and after 24 h, the cells remained uninduced
or induced for MCPyV ST expression. Immunoblotting with a
stathmin-specific antibody confirmed efficient knockdown (Fig.
6A). Similar results were observed in the presence of the scram-
bled siRNA control, as shown in Fig. 2B, where an increase in cell
motility is observed upon MCPyV ST expression, resulting in a
more rapid gap closure (Fig. 6B). In contrast, cellular growth back
was inhibited in MCPyV ST-expressing i293-ST cells depleted for
stathmin (Fig. 6B). Notably, these data demonstrate that stathmin
is required for MCPyV ST-enhanced cell motility and migration.
Cellular phosphatases are required for MCPyV ST-mediated
microtubule destabilization and cell motility. The results sug-
gest that MCPyV ST increases the pool of unphosphorylated
FIG 4 MCPyV ST promotes microtubule destabilization. MCC13 cells were transfected with either EGFP or EGFP-ST expression vectors. After 24 h, cells were
fixed and permeabilized, and GFP fluorescence was analyzed by direct visualization, whereas endogenous stathmin (A) and endogenous -tubulin (B) were
identified by indirect immunofluorescence using stathmin- and -tubulin-specific antibodies, respectively. (C) MCC13 cell lysates expressing EGFP or EGFP-ST
were analyzed by immunoblotting using stathmin-, phosphorylated stathmin-, acetylated tubulin-, GFP-, and -tubulin-specific antibodies. (D) Cellular lysates
from MCC13 (MCPyV-negative) and MKL-1 (MCPyV-positive) cells were analyzed by immunoblotting using stathmin-, phosphorylated stathmin-, acetylated
tubulin-, 2T2-, and -tubulin-specific antibodies.
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stathmin levels. As MCPyV ST interacts with multiple cellular
phosphatase subunits, including PP2A A, PP2A A, and
PP4C (10, 15), we assessed whether cellular phosphatases are
required for microtubule destabilization and cell motility using
two previously generated MCPyV ST mutants that fail to inter-
act with PP2A A (the R7A mutant) or PP4C and PP2A A (the
95-111 mutant) (15). Importantly, these mutants still retain
other MCPyV ST functions (15). MCC13 cells expressing
EGFP, EGFP-ST, EGFP-R7A, or EGFP95-111 were stained
with a -tubulin-specific antibody to determine the presence of
a stable microtubule network (Fig. 7A). R7A (PP2A A) re-
tained the ability to destabilize microtubules. Conversely, a stable
microtubule network was evident in EGFP95-111-expressing cells
(PP4C/PP2A A). To confirm these observations, immunoblotting
was performed with stathmin-, phosphorylated stathmin-, and acety-
lated tubulin-specific antibodies on MCC13 transfected cell lysates
(Fig. 7B). Increased levels of phosphorylated stathmin and acetylated
tubulin were observed in EGFP95-111-expressing cells, compared
to EGFP-ST- and EGFP-R7A-expressing cells, indicating increased
microtubule stabilization. To test the requirement for cellular phos-
phatases in MCPyV ST-induced cell motility, scratch assays were per-
formed with MCC13 cells (Fig. 7C) expressing EGFP, EGFP-ST,
EGFP-R7A, or EGFP95-111. The results demonstrate that cellular
growth back was reduced in the EGFP95-111-expressing compared
to the EGFP-R7A- and MCPyV EGFP-ST-expressing cells. Together,
the results suggest that PP4C and/or PP2A A is required for MCPyV
ST-induced cell motility and migration.
Similar assays were also performed using wild-type or trans-
FIG 5 Microtubule destabilization is required for MCPyV ST-mediated cell motility. (A) MCC13 cells expressing EGFP or EGFP-ST were incubated in the
presence of paclitaxel. After 24 h, cells were fixed and permeabilized, and GFP fluorescence was analyzed by direct visualization, whereas endogenous -tubulin
was identified by indirect immunofluorescence using a -tubulin-specific antibody. (B) (i) MCC13 cells were transfected with either EGFP or EGFP-ST
expression vectors and also incubated in the absence or presence of paclitaxel. After 24 h, a scratch was created by scraping the monolayer, migration of cells
toward the scratch was observed over a 24-h period, and images were taken at 0 and 24 h under a Zeiss light microscope at 	4 magnification. (ii) The size of the
wound was measured at 0 and 24 h. Scratch assays were performed in triplicate. (C) (i) MKL-1 cells were transduced with lentivirus-based vectors expressing
shRNAs targeting ST alone, both LT and ST (PanT), and a scrambled negative control (Con). Cellular lysates were then analyzed by immunoblotting using
stathmin-, phosphorylated stathmin-, acetylated tubulin-, and MCPyV T antigen (2T2)-specific antibodies. GAPDH was used as a measure of equal loading. (D)
Precoated Matrigel-based Transwell migration tissue culture plates were seeded with MKL-1 cells transduced with scrambled (control)-, ST-, or ST-LT
(PanT)-targeting lentivirus-based vectors. HT1080 cells, an invasive human fibrosarcoma cell line, were also used as a positive control. Cells were incubated in
the Transwell plates for 22 h and then labeled with calcein AM fluorescent dye for 90 min, and fluorescence was measured. The experiment was performed in
triplicate, and the graph indicates the fluorescence (percentage) of cells moving through the migration plates relative to the uncoated plate, set at 100%.
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dominant mutants of PP2A and PP4. PP2AcH118N, is a catalyti-
cally inactive transdominant mutant of the PP2A catalytic subunit
(63), and PP4-RL is a phosphatase-dead mutant of PP4 (64). The
presence of a stable microtubule network was analyzed using a
-tubulin-specific antibody in MCC13 cells expressing EGFP or
EGFP-ST in the presence of either wild-type or catalytically inac-
tive forms of PP2A or PP4 (Fig. 8A). The results show that expres-
sion of both wild-type cellular phosphatases had little effect on the
ability of MCPyV ST to destabilize microtubules. However, upon
expression of PP2AcH118N, destabilization of the microtubule
network was evident in both control and MCPyV ST-expressing
cells, suggesting that inhibition of PP2A activity induces microtu-
bule destabilization (data not shown). This result has been previ-
ously observed (59, 65), and therefore no further conclusions on
MCPyV ST function could be drawn using this mutant. In con-
trast, expression of PP4-RL had little effect on the microtubule
network in control cells. Notably, however, a stable microtubule
network was evident in MCPyV ST-expressing cells, suggesting
that the PP4C transdominant mutant inhibited MCPyV ST-in-
duced microtubule destabilization (Fig. 8A). To confirm these
observations, immunoblotting was performed with stathmin-,
phosphorylated stathmin-, and acetylated tubulin-specific anti-
bodies on MCC13 cell lysates (Fig. 8B). Similar to EGFP95-111-
expressing cells, increased levels of phosphorylated stathmin and
acetylated tubulin were observed in the presence of the PP4C
transdominant mutant compared to the wild-type construct in
MCPyV ST-expressing cells. We next assessed the effect of PP4-RL
expression on MCPyV ST-induced cell motility using scratch as-
says, comparing MCC13 cells expressing EGFP or EGFP-ST in the
presence of wild-type or the catalytically inactive PP4C (Fig. 8C).
The results demonstrate that cellular growth back was inhibited in
MCPyV ST-expressing cells transfected with the catalytically inac-
tive PP4C, in contrast to wild-type PP4C. Together the results
implicate PP4C in MCPyV ST-induced microtubule destabiliza-
tion and cell motility.
DISCUSSION
MCPyV ST is an oncogenic protein (10). Herein, we show that
MCPyV ST leads to changes in cellular protein levels that regulate
cytoskeletal organization and dynamics. Considering the highly
metastatic nature of MCC, this suggests a possible link between
MCPyV ST and cell motility and migration, essential factors for
tumor cell dissemination. Indeed metastasis to distant sites corre-
lates with poor MCC survival rates (16). MCC is effectively an
accidental endpoint for MCPyV infection, due to the clonally in-
tegrated genome being unable to replicate. However, the promo-
tion of metastasis by virus oncoproteins is not without precedent:
a number of DNA viruses have been shown to induce metastasis
FIG 6 Stathmin is required for MCPyV ST-mediated cell motility. (A) (i) i293-ST cells were transfected with either scrambled siRNA or stathmin-specific siRNA
and after 24 h remained uninduced or were induced with doxycycline hyclate. Cellular lysates were harvested every 24 h over a 72-h period, and immunoblotting
was performed using stathmin- and GAPDH-specific antibodies (ii) Densitometry quantification of the Western blots was carried out using the ImageJ software
and is shown as a percentage of relative densitometry of stathmin normalized to the loading control, GAPDH. (B) (i) Poly-L-lysine-coated 6-well plates were
seeded with i293-ST cells and transfected with either scrambled siRNA or stathmin-specific siRNA, and after a further 12 h, cells either remained uninduced or
were induced with doxycycline hyclate. After 24 h, a scratch was created by scraping the monolayer, migration of cells toward the scratch was observed over a 72-h
period, and images were taken every 24 h under a Zeiss light microscope at 	4 magnification. (ii) The size of the wound was measured at 0 and 72 h. Scratch assays
were performed in triplicate.
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by deregulating the normal processes of cellular adhesion and mo-
tility (66–69).
Stathmin is overexpressed in many cancer types (35, 36), but its
contribution to tumor development is still poorly understood.
The link between stathmin, microtubule destabilization, and cell
motility is supported by the use of two stathmin mutants that
separate its tubulin-sequestering activity, which destabilizes mi-
crotubules, from its catastrophe-promoting ability (35, 70). 3D
Transwell migration and invasion assays overexpressing the wild
type or the mutant containing the tubulin-sequestering activity
dramatically decreased the amount of stable acetylated microtu-
bules enhancing cell migration, in contrast to the catastrophe-
promoting mutant (35). Interestingly, in contrast to 3D matrices
or in vivo analysis, reports have suggested that in certain cell types,
increased stathmin expression is insufficient to enhance cell mo-
tility in 2D time-lapse wound closure assays (35, 71, 72). This
observation has yet to be fully elucidated but may be linked to
distinct molecular mechanisms regulating cell morphology (73,
74). Expression of a less phosphorylated stathmin mutant can
induce a rounded cell shape coupled with amoeboid-like protru-
sions, allowing enhanced movement using bleb-like propulsion
mechanisms (35). It may be the case that stathmin overexpression
leads to a more flexible and dynamic microtubule network, induc-
ing a switch in mechanisms that further regulate additional cell
morphology changes. Notably, bioinformatic analysis identified
gene ontology headers that included general cytoskeletal changes
within the MCPyV ST proteomic data, and work is ongoing to
determine whether additional changes to the host cell actin cyto-
skeleton are induced upon MCPyV ST expression.
The results also suggest that the pool of unphosphorylated
stathmin is increased upon MCPyV ST expression. To date, few
cellular phosphatases have been implicated in the regulation of
stathmin. Okadaic acid-mediated inhibition results in a major in-
crease in the level of phosphorylation of stathmin (75), suggesting
a possible role of protein phosphatases of types 1, 2A, and 2B.
Moreover, in vitro dephosphorylation assays showed differential
patterns of site-specific dephosphorylation, suggesting stathmin
phosphorylation is modulated by the sequential activity of multi-
ple cellular phosphatases (75). MCPyV ST interacts with various
cellular phosphatase subunits, and we highlight a likely role of
FIG 7 Cellular phosphatases are required for MCPyV ST-mediated microtubule destabilization and cell motility. (A) MCC13 cells were transfected with either
EGFP, EGFP-ST, EGFP-R7A, or EGFP-95-111 expression vector. After 24 h, cells were fixed and permeabilized, and GFP fluorescence was analyzed by direct
visualization, whereas endogenous -tubulin was identified by indirect immunofluorescence using a -tubulin-specific antibody. (B) MCC13 cell lysates
transfected with either EGFP, EGFP-ST, EGFP-R7A, or EGFP-95-111 expression vector were analyzed by immunoblotting using stathmin-, phosphorylated
stathmin-, acetylated tubulin-, and EGFP-specific antibodies. GAPDH was used as a measure of equal loading. (C) (i) MCC13 cells were transfected with either
EGFP, EGFP-ST, EGFP-R7A, or EGFP-95-111 expression vector. After 24 h, a scratch was created by scraping the monolayer, migration of cells toward the
scratch was observed over a 24-h period, and images were taken at 0 and 24 h under a Zeiss light microscope at 	4 magnification. (ii) The size of the wound was
measured at 0 and 24 h. Scratch assays were performed in triplicate.
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PP4C in MCPyV ST-induced microtubule destabilization and cell
motility. Interestingly, PP4C has been implicated in microtubule
dynamics and is required for proper microtubule organization at
the centrosome through regulation of NDEL1 and recruitment of
katanin p60 (76).
MCC is treated by surgical excision and radiotherapy, which
can achieve loco-regional control, but a paucity of trials means no
defined chemotherapy regime has proven effective for the meta-
static disease. MCPyV may identify potential novel virus-targeted
therapeutic regimens. For example, YM155, a small-molecule in-
hibitor of the survivin promoter, initiates cell death in virus-pos-
itive MCC cells and significantly delays MCC xenografts (77).
MCPyV ST-induced microtubule destabilization may also be an
avenue for further investigation. Taxanes are widely used in com-
bination with other anticancer drugs to treat many different types
of cancer and may be of therapeutic benefit for MCC, although the
clinical utility of these microtubule inhibitors is often constrained
by primary or acquired resistance. New microtubule-targeting
agents that overcome taxane resistance provide additional options
for treatment. The epothilones have activity against taxane-resis-
tant cell lines and tumor xenografts (61). Therefore, it would be
interesting to determine if epothilones also have inhibitory effects
on MCPyV ST-induced cell migration. Moreover, the upregula-
tion of stathmin by MCPyV ST may also be a novel therapeutic
target. Gene profiling of melanoma cells has identified stathmin as
a potential target of miR-193b, and ectopic expression of miR-
193b results in a decrease in stathmin and reduced migration of
multiple melanoma cell lines (38). As such, RNAi-based therapies
delivering miR-193 mimics or stathmin-specific siRNAs may
prove powerful tools to inhibit metastatic MCC.
In summary, we provide evidence that MCPyV ST promotes
differential expression of cellular proteins implicated in cytoskel-
etal organization and dynamics leading to a motile and migratory
phenotype. We demonstrate the essential role of stathmin in
MCPyV ST-mediated microtubule destabilization and cell motil-
ity and implicate the cellular phosphatase catalytic subunit PP4C
in the regulation of this process. These findings suggest a possible
molecular explanation for the highly metastatic phenotype asso-
FIG 8 PP4C transdominant mutant expression inhibits MCPyV ST-mediated microtubule destabilization and cell motility. (A) MCC13 cells were transfected
with either EGFP or EGFP-ST in the presence of WT PP4C or PP4C transdominant mutant expression vectors. After 24 h, cells were fixed and permeabilized, and
GFP fluorescence was analyzed by direct visualization, whereas endogenous -tubulin was identified by indirect immunofluorescence using a -tubulin-specific
antibody. (B) MCC13 cell lysates transfected with either EGFP or EGFP-ST in the presence of WT PP4C or the PP4C transdominant mutant were analyzed by
immunoblotting using stathmin-, phosphorylated stathmin-, acetylated tubulin-, HA-, FLAG- and EGFP-specific antibodies. GAPDH was used as a measure of
equal loading. (C) (i) MCC13 cells were transfected with either EGFP or EGFP-ST in the presence of WT PP4C or PP4C transdominant mutant expression vector.
After 24 h, a scratch was created by scraping the monolayer, migration of cells toward the scratch was observed over a 24-h period, and images were taken at 0 and
24 h under a Zeiss light microscope at 	4 magnification. (ii) The size of the wound was measured at 0 and 24 h. Scratch assays were performed in triplicate.
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ciated with MCCs and highlight stathmin as a possible biomarker
of MCC prognosis and as a target for novel antitumoral therapies.
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